Publications by authors named "Paul Wannamaker"

Claim this Profile
V
VH3810109 Efficacy, Safety, Pharmacokinetics, and Incidence of Antidrug Antibodies in Adults With HIV-1 Naive to Antiretroviral Therapy: BANNER Study Results.
Peter A Leone, Alejandro Ferro, Charlotte-Paige Rolle, Sergio Lupo, Joseph McGowan, Paul Wannamaker

J Infect Dis· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
VH3810109 (N6LS) broadly neutralizing antibody safety, pharmacokinetics, and anti-drug antibody incidence in adults without HIV: phase 1 SPAN study results.
Peter A Leone, Jan Losos, Paul Wannamaker, Riccardo D'Agostino, Michael Warwick-Sanders

Antimicrob Agents Chemother· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 Trial of Long-Acting Cabotegravir and VRC07-523LS for Viral Suppression in Adults with HIV-1: ACTG A5357.
Babafemi O Taiwo, Yu Zheng, Katherine Rodriguez, Leah Burke, Jacqueline D Reeves, Paul Wannamaker

Clin Infect Dis· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Tolerability, Pharmacokinetics, and Acceptability of Oral and Long-Acting Cabotegravir in HIV-Negative Chinese Men.
Kelong Han, Paul Wannamaker, Hongzhou Lu, Biao Zhu, Meixia Wang

Antimicrob Agents Chemother· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unexpected finding of delayed-onset seizures in HIV-positive, treatment-experienced subjects in the Phase IIb evaluation of fosdevirine (GSK2248761).
David A Margolis, Joseph J Eron, Edwin DeJesus, Scott White, Paul Wannamaker

Antivir Ther· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Similar virologic and immunologic efficacy with fosamprenavir boosted with 100 mg or 200 mg of ritonavir in HIV-infected patients: results of the LESS trial.
Calvin Cohen, Edwin Dejesus, Anthony Lamarca, Benjamin Young, Linda Yau, Paul Wannamaker

HIV Clin Trials· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients.
Kathleen E Squires, Benjamin Young, Edwin Dejesus, Nicholaos Bellos, Daniel Murphy, Paul G Wannamaker

AIDS· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients.
Kathleen E Squires, Benjamin Young, Edwin DeJesus, Nicholas Bellos, Daniel Murphy, Paul G Wannamaker

HIV Clin Trials· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A study of HIV provider attitudes toward HLA-B 5701 testing in the United States.
Maria E Watson, Lisa G Patel, Belinda Ha, Paul Wannamaker, Robert Cuffe

AIDS Patient Care STDS· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
Kimberly Y Smith, Parul Patel, Derek Fine, Nicholaos Bellos, Louis Sloan, Paul Wannamaker

AIDS· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America.
Benjamin Young, Kathleen Squires, Parul Patel, Edwin Dejesus, Nicholaos Bellos, Paul Wannamaker

AIDS· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients.
Michael Saag, Rukmini Balu, Elizabeth Phillips, Philip Brachman, Claudia Martorell, Paul Wannamaker

Clin Infect Dis· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial.
Joseph Eron, Patrick Yeni, Joseph Gathe, Vicente Estrada, Edwin DeJesus, Paul Wannamaker

Lancet· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients.
Amalia Rodriguez-French, Jack Boghossian, Glenda E Gray, Jeffrey P Nadler, Arnaldo R Quinones, Paul G Wannamaker

J Acquir Immune Defic Syndr· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Twice-daily Trizivir versus Combivir-abacavir in antiretroviral-experienced adults with human immunodeficiency virus-1 infection: a formulation-switch trial.
Margaret A Fischl, Alfred E Burnside, Charles E Farthing, Melanie A Thompson, Nicholaos C Bellos, Paul G Wannamaker

Pharmacotherapy· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis